纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | AT |
Uniprot No | Q4VNC1 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-1196aa |
氨基酸序列 | MGHFEKGQHALLNEGEENEMEIFGYRTQGCRKSLCLAGSIFSFGILPLVFYWRPAWHVWAHCVPCSLQEADTVLLRTTDEFQIYSWKKVIWIYLSALNSAFGLTPDHPLMTDEEYIINRAIRKPDLKVRCIKVQKIRYVWNYLEGQFQKIGSLEDWLSSAKIHQKFGSGLTREEQEIRRLICGPNTIDVEVTPIWKLLIKEVLNPFYIFQLFSVCLWFSEDYKEYAFAIIIMSIISISLTVYDLREQSVKLHHLVESHNSITVSVCGRKAGVQELESRVLVPGDLLILTGNKVLMPCDAVLIEGSCVVDEGMLTGESIPVTKTPLPKMDSSVPWKTQSEADYKRHVLFCGTEVIQAKAACSGTVRAVVLQTGFNTAKGDLVRSILYPKPVNFQLYRDAIRFLLCLVGTATIGMIYTLCVYVLSGEPPEEVVRKALDVITIAVPPALPAALTTGIIYAQRRLKKRGIFCISPQRINVCGQLNLVCFDKTGTLTRDGLDLWGVVSCDRNGFQEVHSFASGQALPWGPLCAAMASCHSLILLDGTIQGDPLDLKMFEATTWEMAFSGDDFHIKGVPAHAMVVKPCRTASQVPVEGIAILHQFPFSSALQRMTVIVQEMGGDRLAFMKGAPERVASFCQPETVPTSFVSELQIYTTQGFRVIALAYKKLENDHHATTLTRETVESDLIFLGLLILENRLKEETKPVLEELISARIRTVMITGDNLQTAITVARKSGMVSESQKVILIEANETTGSSSASISWTLVEEKKHIMYGNQDNYINIRDEVSDKGREGSYHFALTGKSFHVISQHFSSLLPKILINGTIFARMSPGQKSSLVEEFQKLDYFVGMCGDGANDCGALKMAHVGISLSEQEASVASPFTSKTPNIECVPHLIKEGRAALVTSFCMFKYMALYSMIQYVGVLLLYWETNSLSNYQFLFQDLAITTLIGVTMNLNGAYPKLVPFRPAGRLISPPLLLSVIFNILLSLAMHIAGFILVQRQPWYSVEIHSACTVQNESISELTMSPTAPEKMESNSTFTSFENTTVWFLGTINCITVALVFSKGKPFRQPTYTNYIFVLVLIIQLGVCLFILFADIPELYRRLDLLCTPVLWRASIVIMLSLNFIVSLVAEEAVIENRALWMMIKRCFGYQSKSQYRIWQRDLANDPSWPPLNQTSHSDMPECGRGVSYSNPVFESNEEQL |
预测分子量 | 133,9 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组抗凝血酶(AT)蛋白的3篇代表性文献示例(部分信息为虚构,仅供格式参考):
1. **文献名称**:Recombinant Antithrombin Production in Escherichia coli: Optimization and Functional Characterization
**作者**:Johnson, R. et al.
**摘要**:本研究通过优化大肠杆菌表达系统,成功实现了重组人抗凝血酶的高效可溶性表达。通过体外活性测定,证实其具有与血浆来源AT相似的肝素结合能力和凝血酶抑制活性。
2. **文献名称**:Structural Analysis of Glycosylated Recombinant Antithrombin III Expressed in CHO Cells
**作者**:Smith, L. et al.
**摘要**:利用CHO细胞表达系统制备糖基化重组AT-III,通过X射线晶体学解析其三维结构,揭示了N-连接糖链对蛋白构象稳定性和抗凝血功能的关键作用,为治疗用重组AT的质量控制提供结构基础。
3. **文献名称**:Phase III Clinical Trial of Recombinant Antithrombin for Hereditary Deficiency Therapy
**作者**:Anderson, C. et al.
**摘要**:针对遗传性AT缺乏症患者的多中心临床试验显示,每周静脉注射重组AT可有效维持血浆AT活性>80%,显著降低静脉血栓发生率(p<0.01),且未发现严重不良反应。
注:实际文献检索建议使用关键词"recombinant antithrombin"或"recombinant AT III"在PubMed/Web of Science等数据库查询。真实研究多集中于表达系统优化(如哺乳动物细胞系改造)、糖基化修饰对药效的影响,以及其在脓毒症、DIC等危重症中的应用评估。
**Background of Recombinant Antithrombin (AT)**
Antithrombin (AT), a key serine protease inhibitor in the hemostatic system, plays a critical role in regulating blood coagulation by neutralizing thrombin, factor Xa, and other clotting enzymes. Naturally synthesized in the liver, AT’s activity is significantly enhanced by heparin, a mechanism vital for preventing excessive clot formation. Hereditary or acquired AT deficiency, though rare, increases thrombosis risk, necessitating therapeutic intervention.
Traditional AT replacement therapies relied on plasma-derived concentrates, which carry potential risks of pathogen transmission and limited supply. Recombinant AT (rAT), produced via genetic engineering in mammalian cell cultures (e.g., CHO cells), emerged as a safer, scalable alternative. The recombinant form mirrors the native protein’s structure and function, including glycosylation patterns essential for stability and heparin-binding affinity.
Approved for clinical use in congenital AT deficiency, rAT is administered to prevent thromboembolic events during high-risk situations like surgery or childbirth. Beyond hereditary cases, it is explored in acquired conditions such as sepsis-induced disseminated intravascular coagulation (DIC) or heparin resistance during cardiac surgeries. Its consistent purity and reduced immunogenicity make it preferable over plasma-derived counterparts.
Research also investigates rAT’s anti-inflammatory and cytoprotective properties, potentially broadening its therapeutic scope. However, challenges like high production costs and the need for frequent dosing due to its short half-life persist. Innovations in protein engineering, such as PEGylation or fusion technologies, aim to enhance pharmacokinetics and efficacy.
Overall, recombinant AT exemplifies the convergence of biotechnology and hematology, offering targeted therapy for coagulation disorders while underscoring the importance of optimizing biologics for clinical and economic viability.
在生物科技领域,蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者,凭借自身卓越的研发实力,每年能成功研发 1000 多种全新蛋白,在重组蛋白领域不断突破。 在重组蛋白生产过程中,艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白,到具有特定催化功能的酶、参与信号传导的激酶,再到用于免疫研究的病毒抗原,艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统,昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势,能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求,从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品,更是从源头到终端的一站式解决方案。从最初的基因合成,精准地构建出符合要求的基因序列,到载体构建,为蛋白表达创造适宜的环境,再到蛋白质表达和纯化,每一个环节都严格把控。我们充分尊重客户的个性化需求,在表达 / 纯化标签的选择、表达宿主的确定等方面,为客户量身定制专属方案。 同时,艾普蒂还配备了多种纯化体系,能够应对不同特性蛋白的纯化需求。这种灵活性和专业性,极大地提高了蛋白表达和纯化的成功率,让客户的研究项目得以顺利推进,在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台,包括: 哺乳动物细胞表达平台:利用哺乳动物细胞精准修饰蛋白,产出与天然蛋白相似的重组蛋白,用于药物研发、细胞治疗等。 杂交瘤开发平台:通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株,优化后的技术让抗体亲和力与特异性更高,应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台:FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞;Beacon® 基于微流控技术,单细胞水平捕获、分析 B 细胞,挖掘抗体多样性,缩短开发周期。 凭借这些平台,艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务,推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富,拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上,艾普蒂生物不仅经验老到,还积累了详实的成功案例。针对客户的工业化生产需求,我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节,对重组蛋白基因序列进行优化,全面探索多种条件,精准找出最契合客户需求的生产方法。 此外,公司还配备了自有下游验证平台,可对重组蛋白展开系统的质量检测与性能测试,涵盖蛋白互作检测、活性验证、内毒素验证等,全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发,确保生产出的蛋白质具备所需的纯度、稳定性与生物活性,这对于保障药物的安全性和有效性起着关键作用 ,与艾普蒂生物共同推动着行业的发展。
×